KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $22.6 million.

  • Castle Biosciences' Cash from Operations fell 302.94% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 455.76%. This contributed to the annual value of $64.9 million for FY2024, which is 125296.84% up from last year.
  • As of Q3 2025, Castle Biosciences' Cash from Operations stood at $22.6 million, which was down 302.94% from $20.8 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Cash from Operations peaked at $24.4 million during Q4 2024, and registered a low of -$25.4 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$3.8 million (2023), whereas its average is $1.9 million.
  • In the last 5 years, Castle Biosciences' Cash from Operations plummeted by 134661.35% in 2021 and then surged by 73386.16% in 2024.
  • Castle Biosciences' Cash from Operations (Quarter) stood at -$2.8 million in 2021, then tumbled by 115.75% to -$6.0 million in 2022, then skyrocketed by 409.78% to $18.6 million in 2023, then soared by 31.09% to $24.4 million in 2024, then dropped by 7.12% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $20.8 million for Q2 2025, and -$6.0 million during Q1 2025.